Plaque IL-1β production is highest in patients with more complex, less stable plaques (58) and conversely, the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) demonstrated that resolution of residual inflammation using a monoclonal antibody targeting IL-1β antibody reduces major adverse cardiovascular events (59). Here, IL1B is linked to deep vein thrombosis.